Halozyme grants director Daly 1,775 stock options

The options expire October 1, 2036, and each restricted stock unit represents a right to receive one share of common stock.

Rhea-AI Filing Summary

Halozyme Therapeutics, Inc. director James M. Daly was granted two compensation awards on October 1, 2026: 1,169 restricted stock units and 1,775 options to purchase common stock, with an exercise price of $106.94 per share. The restricted stock units are scheduled to vest on the date of the Issuer’s 2027 annual meeting, and the options vest in full on that date.

Insider Trade Summary

Grant/Award: 2,944 shares

Grant/Award 2 txns

Insider Daly James M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option to Purchase Common Stock F2	1,775	$0.00	$0.00
Grant/Award	Restricted Stock Units F1	1,169	$0.00	$0.00

Holdings After Transaction: Option to Purchase Common Stock — 1,775 contracts (Direct); Restricted Stock Units — 1,169 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders.
2. F2. Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

Restricted stock units granted: 1,169 units Options to purchase common stock granted: 1,775 options Option exercise price: $106.94 per share +1 more

4 metrics

Restricted stock units granted 1,169 units Director compensation award on October 1, 2026

Options to purchase common stock granted 1,775 options Director compensation award on October 1, 2026

Option exercise price $106.94 per share Options granted on October 1, 2026

Option expiration date October 1, 2036 Granted options

Key Terms

Restricted Stock Units, stock options, vest in full

3 terms

Restricted Stock Units financial

"Represents restricted stock units granted under the Issuer's director compensation program"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

stock options financial

"stock options granted under the Issuer's director compensation program"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

vest in full financial

"This grant will vest in full on the date of the Issuer's 2027 annual meeting"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What awards did HALO director James M. Daly receive?

James M. Daly received 1,169 restricted stock units and 1,775 options to purchase common stock on October 1, 2026. The options have an exercise price of $106.94 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/02/2026 - 04:44 PM Accepted by SEC EDGAR 10/02/2026 - 04:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daly James M

(Last) (First) (Middle)

C/O HALOZYME THERAPEUTICS, INC.

12390 EL CAMINO REAL

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HALOZYME THERAPEUTICS, INC. [ HALO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Restricted Stock Units	10/01/2026		A		1,169(1)	A	$0	1,169	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to Purchase Common Stock	$106.94	10/01/2026		A		1,775		(2)	10/01/2036	Common Stock	1,775	$0	1,775	D

Explanation of Responses:

1. Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the date of the Issuer's 2027 annual meeting of stockholders.

2. Represents stock options granted under the Issuer's director compensation program. This grant will vest in full on the date of the Issuer's 2027 annual meeting of stockholders.

Remarks:

	/s/ James R. Oehler, Attorney-in-Fact	10/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)